<DOC>
	<DOCNO>NCT01502228</DOCNO>
	<brief_summary>Given grow importance anti-angiogenic therapy treatment metastatic renal carcinoma , expect trial establish preliminary data need apply fund large clinical investigation potential role PET perfusion image management renal carcinoma , potentially cancer .</brief_summary>
	<brief_title>PET/CT Assessment Tumor Perfusion Patients With Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Ability understand willingness sign witness , informed consent authorization release health information . Patients diagnosis relapse Stage IV renal cell cancer medically unresponsive prior treatment surgically unresectable metastasis fall within PET/CT fieldofview include heart . Being consider systemic therapy Sunitinib Women pregnant , breastfeeding , childbearing potential use birth control Having telephone reliable way study personal contact Subjects claustrophobic tolerate imaging procedure Subjects weigh &gt; 350 lb . ( upper weight limit scanner bed )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>